arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Decoy Therapeutics Inc.

DCOY
$4.19 ▲ +0.08 (+1.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
50 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
8
Health
Poor
Bearish
auto_awesome

Analytical Summary

Decoy Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -46.5%
FCF / Share $-5.43
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.22M
↓ -30.1%
Operating Margin Operating profit as % of sales
-142.2%
↓ -19.7%
FCF / Share Free cash flow per share
$-5.43
↑ +49.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
3
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters